Analysis of Next Generation Sequencing Data Final Project Presentation

Differential Expression Analysis of RNA-seq Data Derived from Alzheimer's Patient Microglia



Presentation Structure

- 1. Introduction
- 2. Results
- 3. Methods
- 4. Discussion

Introduction

Alzheimer's, Microglia and Reference Study




Alzheimer's Disease

- Alzheimer's disease (AD) effects approximately 5.8 million people in the the United States ages 65 and older
 - Early sign and symptoms of the disease centering around forgetfulness
 - Impairment of memory follows, until loss of ability to carry out everyday tasks
- There is currently no treatment that cures AD or alters the disease process in the brain -- Mayo Clinic
 - Important to continue research in the area
 - O Possibly NAD therapies: Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models


Alzheimer's Patient Microglia Exhibit Enhanced Aging and Unique Transcriptional Activation

- Recent genetic studies of humans have identified brain specific myeloid cells (microglia) as a potential key cell type controlling an individual's risk of acquiring Alzheimer's Disease
- This study identified 45
 differentially expressed
 genes between Control and
 AD Microglia (Myeloid) cells



Study Hypothesis

- Given scrutinous quality control and industry standard tools such as STAR and DESeq2, I will achieve a different set of differentially expressed genes than shown final in the reference publication
 - "Sorted cell and whole tissue RNA-Seq data were analyzed using the GSNAP aligner and HTSeqGenie"




Results

DE Genes, Volcano Plot, Gene Ontology Treemap




Differentially Expressed Genes

- Confirmed 38 genes to be differentially expressed between control and AD clinical groups
- Same 14 genes supported by my analyses, reference paper, and study-found literature-supported AD risk genes



Differential Expression Volcano Plot



Gene Ontology Treemap -- Bio. Func.

REVIGO TreeMap dynorphin metal receptor uracil NADP nucleobase chelating binding binding binding activity phosphatidylcholine-sterol O-acyltransferase activator activity ferric-chelate dihydropyrimidine cerebroside-sulfatase reductase dehydrogenase AF-2 domain activity (NADP+) (NADPH) binding activity activity

Methods






Downloading Data


- Data Available through NCBI GEO Accession Number
 - SRA Runs Selector
 - 113 total isolated-cell samples
 - 25 Myeloid samples
 - Age, APOE genotype,
 Sex, PMI metadata
 available


▲ Run	♦ BioSample	◆ APOE	Bases	♦ Bytes	Cell_type 6	Diagnosis Diagnosis
SRR8440443	SAMN10741236	3/3	2.27 G	694.72 Mb	myeloid	Control
SRR8440444	SAMN10741241	3/3	2.19 G	683.21 Mb	endothelial	Control
SRR8440445	SAMN10741240	3/3	2.17 G	700.85 Mb	neuron	Control
SRR8440446	SAMN10741239	3/4	2.44 G	791.87 Mb	neuron	AD
SRR8440447	SAMN10741238	NA	2.14 G	648.79 Mb	myeloid	Control
SRR8440448	SAMN10741237	3/4	2.16 G	664.66 Mb	myeloid	AD
SRR8440449	SAMN10741235	2/3	2.16 G	653.94 Mb	myeloid	Control
SRR8440450	SAMN10741234	2/3	2.99 G	940.45 Mb	endothelial	Control
SRR8440451	SAMN10741233	3/3	2.91 G	902.51 Mb	endothelial	AD
SRR8440452	SAMN10741232	3/3	2.46 G	793.50 Mb	neuron	Control
SRR8440453	SAMN10741231	3/3	2.34 G	766.49 Mb	neuron	AD
SRR8440454	SAMN10741230	3/3	2.47 G	789.37 Mb	neuron	AD
SRR8440455	SAMN10741229	3/3	2.24 G	829.08 Mb	endothelial	Control
SRR8440456	SAMN10741228	3/3	4.10 G	1.24 Gb	astrocyte	Control
SRR8440457	SAMN10741286	2/3	10.49 G	3.24 Gb	astrocyte	Control
SRR8440458	SAMN10741285	2/2	201G	650 22 Mh	neuron	Control

Raw Data FastQC

- At first detected Illumina adapters
 - TrimGalore
- 3 samples had cyclic GC content
 - No per-tile information available
- Skewed GC content found in 1 sample
 - 72 year old male with AD and 4/4 APOE genotype









RNA-Seq Alignment with STAR

- Same 72 YO male sample seen with skewed GC content also has 33.79% of reads failing to map to human HG38 Genome
- Other samples look fairly uniform (5-10% of reads not mapping)




```
Percentage of unmapped reads for SRR8440443: 5.90%
Percentage of unmapped reads for SRR8440447: 4.17%
Percentage of unmapped reads for SRR8440448: 4.04%
Percentage of unmapped reads for SRR8440449: 8.38%
Percentage of unmapped reads for SRR8440463: 33.79%
Percentage of unmapped reads for SRR8440477: 5.14%
Percentage of unmapped reads for SRR8440482: 6.54%
Percentage of unmapped reads for SRR8440484: 3.65%
Percentage of unmapped reads for SRR8440486: 8.13%
Percentage of unmapped reads for SRR8440488: 5.19%
Percentage of unmapped reads for SRR8440501: 6.98%
Percentage of unmapped reads for SRR8440511: 5.47%
Percentage of unmapped reads for SRR8440513: 6.79%
Percentage of unmapped reads for SRR8440514: 4.97%
Percentage of unmapped reads for SRR8440517: 5.76%
Percentage of unmapped reads for SRR8440518: 5.02%
Percentage of unmapped reads for SRR8440524: 11.28%
Percentage of unmapped reads for SRR8440525: 9.51%
Percentage of unmapped reads for SRR8440527: 7.05%
Percentage of unmapped reads for SRR8440529: 6.67%
Percentage of unmapped reads for SRR8440531: 10.64%
Percentage of unmapped reads for SRR8440536: 7.61%
Percentage of unmapped reads for SRR8440538: 7.43%
Percentage of unmapped reads for SRR8440539: 12.34%
Percentage of unmapped reads for SRR8440542: 8.16%
```

Read Count Normalization -- Size Factors




Gene Filtering

- Tissue from frozen samples
 - High IncRNA and Mitochondrial RNA content
- Filtered for only non-Mitochondrial protein-coding genes
 - Study does not, and identifies many mitochondrial associated differentially expressed genes



Literature-Supported Gene Set

- Did not find clinical group separation with rlog normalized gene expression, or top 300-1000 variable genes
- Study identifies 25 literature-supported AD-risk genes
 - Used in exploratory data analysis phase




Differentially Expressed Genes

- Confirmed 14 genes to be differentially expressed between control and AD clinical groups
- Same 14 genes appear in paper as gathered literature-supported AD risk genes, and appear in final DE gene list of paper

	padj	log2FoldChange
SERPINF1	0.000041	1.7407
CECR2	0.000041	1.6923
TGFBI	0.004718	-1.9188
GLT1D1	0.005319	2.4133
ARSA	0.019995	-1. <mark>275</mark> 2
PTPRG	0.019995	-1.7361
S100A4	0.019995	-3.5340
APOE	0.019995	-1.5115
MOV10L1	0.037131	2.5397
ASTN1	0.041758	1.4381
DPYD	0.042672	-1.8551
STEAP3	0.044855	-1.4818
IGSF10	0.048952	1.5660
PSTPIP1	0.048952	-1.8852

Differential Expression Volcano Plot



Gene Ontology Treemap -- Bio. Func.

REVIGO TreeMap dynorphin metal receptor uracil NADP chelating nucleobase binding binding binding activity phosphatidylcholine-sterol O-acyltransferase activator activity ferric-chelate dihydropyrimidine cerebroside-sulfatase reductase dehydrogenase AF-2 domain activity (NADP+) (NADPH) binding activity activity


Discussion

Limitation of Scope, Interesting Identified Genes



Limitations and Findings

- Scope was limited due to high IncRNA and Mitochondrial RNA content
 - Could only confirm protein-coding genes
 - IncRNAs in DE list of study
- However, genes that were confirmed are interesting
 - Confirmation from literature, reference study and my own DE gene list



Interesting Identified Genes

SERPINF1 (serpin family F member 1) – The encoded protein is secreted and strongly **inhibits angiogenesis**. In addition, this protein is a **neurotrophic factor** involved in neuronal differentiation in retinoblastoma cells. Mutations in this gene were found in individuals with osteogenesis imperfecta.

CECR2 (CECR2 histone acetyl-lysine reader) – Involved in chromatin remodeling, and may additionally play a role in **DNA damage response**. The encoded protein functions as part of an ATP-dependent complex that is involved in neurulation.

ARSA (arylsulfatase A) – Defects in this gene lead to metachromatic leucodystrophy (MLD), a progressive demyelination disease which results in a **variety of neurological symptoms** and ultimately death.

S100A4 (S100 calcium binding protein A4) – S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation.

	padj	log2FoldChange
SERPINF1	0.000041	1.7407
CECR2	0.000041	1.6923
TGFBI	0.004718	-1.9188
GLT1D1	0.005319	2.4133
ARSA	0.019995	-1.2752
PTPRG	0.019995	-1.7361
S100A4	0.019995	-3.5340
APOE	0.019995	-1.5115
MOV10L1	0.037131	2.5397
ASTN1	0.041758	1.4381
DPYD	0.042672	-1.8551
STEAP3	0.044855	-1.4818
IGSF10	0.048952	1.5660
PSTPIP1	0.048952	-1.8852

